Medicamen Biotech Intrinsic Value
MEDICAMEQ Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹137.28 | ₹109.82 - ₹164.74 | -64.8% | EPS: ₹6.24, Sector P/E: 22x |
| Book Value Method | asset | ₹327.69 | ₹294.92 - ₹360.46 | -16.0% | Book Value/Share: ₹163.85, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹295.38 | ₹265.84 - ₹324.92 | -24.3% | Revenue/Share: ₹147.69, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹180.81 | ₹162.73 - ₹198.89 | -53.7% | EBITDA: ₹24.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹156.10 | ₹124.88 - ₹187.32 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹117.07 | ₹105.36 - ₹128.78 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹117.07 | ₹105.36 - ₹128.78 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹151.67 | ₹136.50 - ₹166.84 | -61.1% | EPS: ₹6.24, BVPS: ₹163.85 |
Want to compare with current market value? Check MEDICAMEQ share price latest .
Valuation Comparison Chart
MEDICAMEQ Intrinsic Value Analysis
What is the intrinsic value of MEDICAMEQ?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Medicamen Biotech (MEDICAMEQ) is ₹156.10 (median value). With the current market price of ₹390.25, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹117.07 to ₹327.69, indicating ₹117.07 - ₹327.69.
Is MEDICAMEQ undervalued or overvalued?
Based on our multi-method analysis, Medicamen Biotech (MEDICAMEQ) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 27.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.39 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 3.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.65x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Medicamen Biotech
Additional stock information and data for MEDICAMEQ
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-8 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-7 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-6 Cr | ₹-9 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹4 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹13 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |